Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.43 |
| ▸ | DRD3 | P35462 | 7/20 | 0.43 |
| ▸ | HTR1A | P08908 | 15/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7392335 | 0.79 | HTR1A (0.58) | DRD2DRD3HTR1AHTR2CHTR2A | |
| SCHEMBL7908059 | 0.79 | HTR1A (0.58) | DRD2DRD3HTR1AHTR2CHTR2A | |
| SCHEMBL29532101 | 0.79 | HTR1A (0.58) | DRD2DRD3HTR1AHTR2CHTR2A | |
| SCHEMBL7350618 | 0.74 | HTR1A (0.66) | DRD2DRD3HTR1A | |
| SCHEMBL7903342 | 0.72 | HTR1A (0.39) | DRD2DRD3HTR1AHTR2CHTR2A | |
| SCHEMBL7903471 | 0.72 | HTR1A (0.39) | DRD2DRD3HTR1AHTR2CHTR2A | |
| SCHEMBL15699092 | 0.72 | MEN1 (0.42) | DRD2DRD3HTR1AHTR2CHTR2A | |
| SCHEMBL7122123 | 0.69 | HTR1A (0.38) | DRD2DRD3HTR1AHTR2CHTR2A | |
| SCHEMBL8844104 | 0.69 | HTR1A (0.38) | DRD2DRD3HTR1AHTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL8844298 | 0.68 | HTR1A (0.39) | DRD2DRD3HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6201119-B1 | 2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPIN-9-AMINE COMPOUNDS USEFUL AS INTERMEDIATES TO ANTIVIRALS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-03-13 | — | — | US | disclosed |
| US-5371079-A | Administering to inhibit replication of HIV-1 in human cells | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-06 | — | — | US | disclosed |
| US-5270464-A | Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-12-14 | — | — | US | disclosed |
| EP-0538297-A1 | ANTIVIRAL TETRAHYDROIMIDAZO 1,4]BENZODIAZEPIN-2-(THIO)ONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000979-A1 | ANTIVIRAL TETRAHYDROIMIDAZO[1,4]BENZODIAZEPIN-2-(THIO)ONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-01-23 | — | — | WO | disclosed |